Brief: Alterity Therapeutics Says UK Regulatory Authorisation To Proceed With Phase 2 Trial Of ATH434
27/04/2022 03:10
April 27 (Reuters) - Alterity Therapeutics Ltd ATH.AX :
* UK REGULATORY AUTHORISATION TO PROCEED WITH PHASE 2 TRIAL
OF
ATH434
Source text for Eikon: ID:nASXsbwyt
Further company coverage: ATH.AX
Recent news on Alterity Therapeutics
See all newsBrief: Alterity Therapeutics Achieves Alignment With U.S. FDA On Pivotal Phase 3 Program For Ath434 In Multiple System Atrophy
Brief: Alterity Therapeutics Receives Positive FDA Feedback On Ath434 Phase 3 Program
Brief: Alterity Therapeutics Says Julian Barbaczy Appointed Non-Exec Chair
Brief: Alterity Therapeutics Raises A$20.0 Million In Strategic Placement
Brief: Alterity Therapeutics Ltd Raises A$20 Million In Capital